Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-CTAG vs D-CAG in Elderly AML
NCT05382390Phase 3Recruiting
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human thrombopoietin in acute myeloid leukemia (AML) (2 arms). Primary endpoint: Overall Survival at 2 years. Started Jan 2022; status: recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05382390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382390.